迈普医学
(301033)
| 流通市值：41.32亿 | | | 总市值：49.09亿 |
| 流通股本：5606.74万 | | | 总股本：6661.19万 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 157,777,674.14 | 73,703,893.55 | 278,442,127.39 | 190,940,750.31 |
| 营业收入 | 157,777,674.14 | 73,703,893.55 | 278,442,127.39 | 190,940,750.31 |
| 利息收入 | - | 0 | - | - |
| 已赚保费 | - | 0 | - | - |
| 手续费及佣金收入 | - | 0 | - | - |
| 二、营业总成本 | 107,860,363.58 | 48,479,325.85 | 202,578,024.19 | 139,545,635.69 |
| 营业成本 | 30,628,424.06 | 14,356,380.8 | 57,563,558.12 | 41,588,231.59 |
| 利息支出 | - | 0 | - | - |
| 手续费及佣金支出 | - | 0 | - | - |
| 退保金 | - | 0 | - | - |
| 赔付支出净额 | - | 0 | - | - |
| 提取保险合同准备金净额 | - | 0 | - | - |
| 保单红利支出 | - | 0 | - | - |
| 分保费用 | - | 0 | - | - |
| 税金及附加 | 3,086,711.34 | 1,448,604.63 | 5,209,252.99 | 3,607,520.86 |
| 销售费用 | 27,889,019.94 | 11,675,610.94 | 57,205,636.83 | 33,292,798.19 |
| 管理费用 | 30,344,696.2 | 14,110,660.44 | 56,832,710.86 | 44,848,008.18 |
| 研发费用 | 17,372,330.53 | 7,846,308.01 | 27,090,650.72 | 16,632,975.62 |
| 财务费用 | -1,460,818.49 | -958,238.97 | -1,323,785.33 | -423,898.75 |
| 其中:利息费用 | 15,548.61 | 10,356.64 | 904,084.36 | 888,216.54 |
| 其中:利息收入 | 1,058,225.55 | 799,326.97 | 2,050,272.24 | 1,446,558.42 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -446,766.21 | -594,552.73 | 151,575.36 | -57,064.1 |
| 加:投资收益 | 1,785,129.36 | 1,188,297.56 | 3,428,431.47 | 2,915,266.01 |
| 汇兑收益 | - | 0 | - | - |
| 资产处置收益 | - | - | 790.78 | 790.78 |
| 资产减值损失(新) | -9,077.79 | -29,560.99 | -69,976.92 | -837.3 |
| 信用减值损失(新) | 32,145.23 | -32,994.93 | -95,828.86 | -15,481.67 |
| 其他收益 | 5,590,659.4 | 2,779,303.07 | 12,442,950.53 | 8,777,949.07 |
| 四、营业利润 | 56,869,400.55 | 28,535,059.68 | 91,722,045.56 | 63,015,737.41 |
| 加:营业外收入 | 59,159.97 | 58,383.66 | 2,613,416.1 | 10,816.77 |
| 减:营业外支出 | 2,114,766.72 | 277,450.96 | 1,178,367.28 | 338,820.34 |
| 五、利润总额 | 54,813,793.8 | 28,315,992.38 | 93,157,094.38 | 62,687,733.84 |
| 减:所得税费用 | 7,514,651.1 | 4,153,685.38 | 14,302,864.15 | 9,884,757.5 |
| 六、净利润 | 47,299,142.7 | 24,162,307 | 78,854,230.23 | 52,802,976.34 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 47,299,142.7 | 24,162,307 | 78,854,230.23 | 52,802,976.34 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 47,299,142.7 | 24,162,307 | 78,854,230.23 | 52,802,976.34 |
| 扣除非经常损益后的净利润 | 45,996,448.89 | 22,924,937.92 | 68,113,273.78 | 46,087,654.7 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.71 | 0.37 | 1.2 | 0.8 |
| (二)稀释每股收益 | 0.71 | 0.36 | 1.2 | 0.8 |
| 八、其他综合收益 | 158,942.97 | 51,005.19 | 7,467.26 | 70,664.75 |
| 归属于母公司股东的其他综合收益 | 158,942.97 | 51,005.19 | 7,467.26 | 70,664.75 |
| 九、综合收益总额 | 47,458,085.67 | 24,213,312.19 | 78,861,697.49 | 52,873,641.09 |
| 归属于母公司股东的综合收益总额 | 47,458,085.67 | 24,213,312.19 | 78,861,697.49 | 52,873,641.09 |
| 公告日期 | 2025-08-22 | 2025-04-25 | 2025-04-25 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |